Symptom-centric view

Skeletal injury

Substances reporting Skeletal injury disproportionately — ranked by ROR.

Pain Drug ineffective Off label use Fatigue Dyspnoea Acute kidney injury

showing 15 of 15

Substance ↓	ROR [95% CI]	Reports	Category	Label
tenofovir disoproxil fumarate —	1758.3 [1666.7–1855.0]	8,676	algemeen	new
tenofovir alafenamide —	452.6 [434.8–471.1]	4,659	algemeen	new
rilpivirine hydrochloride —	872.3 [832.1–914.4]	2,977	algemeen	new
rilpivirine —	387.9 [371.0–405.6]	2,977	algemeen	new
emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate —	1899.0 [1799.9–2003.6]	2,771	algemeen	new
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide —	309.3 [279.9–341.8]	461	algemeen	new
emtricitabine and tenofovir disoproxil fumarate —	1292.2 [1236.2–1350.7]	7,462	algemeen	new
emtricitabine and tenofovir alafenamide —	486.9 [467.5–507.1]	4,376	algemeen	new
emtricitabine —	1061.6 [1012.3–1113.3]	8,084	algemeen	new
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate —	1424.0 [1355.2–1496.2]	3,021	algemeen	new
elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide —	466.3 [440.5–493.6]	1,649	algemeen	new
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide —	327.5 [293.0–366.1]	371	algemeen	new
darunavir —	47.0 [42.6–51.8]	423	algemeen	new
cobicistat —	800.3 [767.1–834.9]	4,077	algemeen	new
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate —	339.2 [322.6–356.7]	2,120	algemeen	new

ROR = reporting odds ratio vs. the full FAERS corpus. A signal is not a cause. Source: openFDA (FAERS).